NovoCure's Non-Current Deffered Revenue fell 8222.86% to $807000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $807000.0, marking a year-over-year decrease of 8222.86%. This contributed to the annual value of $2.9 million for FY2022, which is 5556.58% down from last year.
Latest data reveals that NovoCure reported Non-Current Deffered Revenue of $807000.0 as of Q2 2023, which was down 8222.86% from $1.8 million recorded in Q1 2023.
In the past 5 years, NovoCure's Non-Current Deffered Revenue ranged from a high of $12.1 million in Q4 2020 and a low of $807000.0 during Q2 2023
Its 5-year average for Non-Current Deffered Revenue is $7.0 million, with a median of $7.9 million in 2019.
As far as peak fluctuations go, NovoCure's Non-Current Deffered Revenue skyrocketed by 5548.87% in 2020, and later plummeted by 8222.86% in 2023.
Over the past 5 years, NovoCure's Non-Current Deffered Revenue (Quarter) stood at $7.8 million in 2019, then skyrocketed by 55.49% to $12.1 million in 2020, then crashed by 46.64% to $6.5 million in 2021, then plummeted by 55.57% to $2.9 million in 2022, then plummeted by 71.96% to $807000.0 in 2023.
Its Non-Current Deffered Revenue stands at $807000.0 for Q2 2023, versus $1.8 million for Q1 2023 and $2.9 million for Q4 2022.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value